| 2025-12-09 |
复牌提示：
2025-12-08 19:50:00 停牌，复牌日期 2025-12-10 00:00:01
|
| 2025-12-09 |
详情>>
内部人交易：
Young Jonathan等共交易19笔
|
| 2025-11-07 |
股东大会：
将于2025-12-02召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger (which we refer to, as it may be amended from time to time, as the “Merger Agreement”), dated October 9, 2025, by and among Akero, Novo Nordisk A/S, a Danish aktieselskab (which we refer to as “Novo” or “Parent”), and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Parent (which we refer to as “Merger Sub”), including the form of contingent value rights agreement (which we refer to as the “CVR Agreement”) to be entered into at or immediately prior to the effective time of the Merger by a direct or indirect wholly owned subsidiary of Parent designated in the CVR Agreement, a rights agent selected by Parent and reasonably acceptable to Akero and, solely with respect to Section 6.11 of the CVR Agreement, Parent, subject to changes permitted by the Merger Agreement. Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into Akero (which we refer to as the “Merger”), with Akero surviving the Merger as a wholly owned subsidiary of Parent (we refer to this proposal, collectively, as the “Merger Proposal”);
2.To consider and vote on the proposal to approve, by non-binding, advisory vote, compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger (we refer to this proposal as the “Compensation Proposal”);
3.To consider and vote on any proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the adoption of the Merger Agreement at the time of the Special Meeting (we refer to this proposal as the “Adjournment Proposal”).
|
| 2025-11-07 |
详情>>
股本变动：
变动后总股本8232.44万股
|
| 2025-11-07 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.76美元,归母净利润-2.23亿美元,同比去年增长-22.39%
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-1.76美元,归母净利润-1.41亿美元,同比去年增长-29.18%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-0.9美元,归母净利润-7072.5万美元,同比去年增长-32.58%
|
| 2025-04-28 |
股东大会：
将于2025-06-03召开股东大会
会议内容 ▼▲
- 1.To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers;
4.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2025-02-28 |
详情>>
业绩披露：
2022年年报每股收益-2.87美元,归母净利润-1.12亿美元,同比去年增长-11.17%
|
| 2025-02-28 |
详情>>
业绩披露：
2024年年报每股收益-3.75美元,归母净利润-2.52亿美元,同比去年增长-66.09%
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.76美元,归母净利润-1.82亿美元,同比去年增长-88.5%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-1.7美元,归母净利润-1.09亿美元,同比去年增长-92.1%
|
| 2024-08-09 |
详情>>
业绩披露：
2023年中报每股收益-1.15美元,归母净利润-5691.4万美元,同比去年增长-6.52%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.9美元,归母净利润-5334.4万美元,同比去年增长-106.51%
|
| 2024-04-26 |
股东大会：
将于2024-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three class II directors, Seth L. Harrison, M.D., Graham Walmsley, M.D., Ph.D., and Yuan Xu, Ph.D., to our board of directors, to serve until the 2027 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers;
4.To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of Akero Therapeutics, Inc. as permitted by recent amendments to Delaware law;
5.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-2.89美元,归母净利润-1.52亿美元,同比去年增长-35.46%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.87美元,归母净利润-9657.3万美元,同比去年增长-8.54%
|
| 2023-04-28 |
股东大会：
将于2023-06-23召开股东大会
会议内容 ▼▲
- 1.To elect three class I directors, Andrew Cheng, M.D., Ph.D., Jane Henderson and Mark Iwicki, to our board of directors, to serve until the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers;
4.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2022-04-28 |
股东大会：
将于2022-06-02召开股东大会
会议内容 ▼▲
- 1.To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2025 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers;
4.To consider and act upon a non-binding, advisory vote on the frequency of future non-binding advisory votes on the compensation paid to our named executive officers;
5.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-01召开股东大会
会议内容 ▼▲
- 1.To elect three class II directors, Seth L. Harrison, M.D., Graham Walmsley, M.D., Ph.D, and Yuan Xu, Ph.D., to our board of directors, to serve until the 2024 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his or her earlier death, resignation or removal
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2020-04-27 |
股东大会：
将于2020-06-01召开股东大会
会议内容 ▼▲
- 1.To elect three class I directors, Andrew Cheng, M.D., Ph.D, Jane Henderson and Mark Iwicki, to our board of directors, to serve until the 2023 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|